Table 1.
Characteristics of Women With Brain Metastases Who Have Undergone Whole Brain Radiation Therapy
| Characteristics | HER-2 Positive | HER-2 Negative |
P | ||
|---|---|---|---|---|---|
| No.(%) | 101 | (45.3) | 122 | (54.7) | |
| Median age at CNS metastases diagnoses, y (range) | 49 (26-79) | – | 50.5 (27-77) | – | – |
| Median time to brain metastases, mo (range) | 12 (0-134) | – | 11.5 (0-91) | – | – |
| Menopausal status at primary breast cancer diagnosis, No. (%) | |||||
| Premenopausal | 53 | (53.54) | 59 | (49.2) | |
| Postmenopausal | 46 | (46.5) | 61 | (50.8) | .52 |
| Trastuzumab, No. (%) | |||||
| Before brain metastases | 22 | (21.8) | – | – | |
| After brain metastases | 79 | (78.2) | – | – | – |
| Race, No. (%) | |||||
| White | 70 | (48.0) | 76 | (62.3) | |
| Black | 14 | (13.9) | 24 | (19.7) | |
| Other | 17 | (16.8) | 22 | (18.0) | .46 |
| T classification, No. (%) | |||||
| T1 | 19 | (18.8) | 32 | (26.2) | |
| T2 | 36 | (35.6) | 57 | (46.7) | |
| T3 | 9 | (8.9) | 15 | (12.3) | |
| T4 | 32 | (31.7) | 18 | (14.7) | |
| TX | 5 | (4.9) | 0 | 0 | .002 |
| N classification, No. (%) | |||||
| N0 | 20 | (19.8) | 47 | (38.5) | |
| N1 | 43 | (42.6) | 47 | (38.5) | |
| N2 | 14 | (13.9) | 14 | (11.5) | |
| N3 | 20 | (19.8) | 10 | (8.2) | |
| NX | 4 | (4.0) | 4 | (4.3) | .022 |
| Stage of disease, No. (%) | |||||
| I | 9 | (9.3) | 21 | (17.4) | |
| II | 30 | (30.9) | 43 | (35.5) | |
| III | 38 | (39.2) | 31 | (25.6) | |
| IV | 20 | (20.6) | 26 | (21.4) | .11 |
| No. of positive lymph nodes, No. (%) | |||||
| <10 | 69 | (85.2) | 93 | (92.1) | |
| >10 | 12 | (14.8) | 8 | (7.9) | .14 |
| Hormone receptor (ER/PR), No. (%) | |||||
| Negative | 55 | (54.5) | 54 | (44.6) | |
| Positive | 46 | (45.5) | 67 | (55.4) | .14 |
| Grade of primary breast tumor, No. (%) | |||||
| 1/2 | 16 | (17.8) | 17 | (14.8) | |
| 3 | 74 | (82.2) | 98 | (85.2) | .56 |
| Lymphovascular invasion of primary breast tumor, No. (%) | |||||
| No | 45 | (53.6) | 73 | (68.2) | |
| Yes | 39 | (46.4) | 34 | (31.8) | .039 |
| Site of first metastases, No. (%) | |||||
| Visceral only | 35 | (34.6) | 34 | (27.9) | |
| Bone only | 7 | (31.8) | 15 | (12.3) | |
| Brain only | 8 | (7.9) | 9 | (7.4) | |
| Multiple | 40 | (39.6) | 38 | (31.2) | |
| Other | 11 | (10.9) | 26 | (21.3) | .13 |
| Extracranial metastases, No. (%) | |||||
| No | 8 | (7.9) | 7 | (5.7) | |
| Yes | 93 | (92.1) | 115 | (94.3) | 052 |
| No. of brain metastases, No. (%) | |||||
| 1 | 9 | (8.9) | 20 | (16.4) | |
| 2 | 5 | (5.0) | 15 | (12.3) | |
| 3 | 5 | (5.0) | 8 | (6.6) | |
| >3 | 82 | (81.2) | 79 | (64.8) | .046 |
| WBRT, No. (%) | |||||
| Alone | 82 | (81.2) | 100 | (82.0) | |
| Plus surgery | 14 | (13.9) | 19 | (15.6) | |
| Plus radiosurgery | 5 | (5.0) | 3 | (2.5) | .59 |
| Radiation dose, Gy, No. (%) | |||||
| <30 | 4 | (4.0) | 11 | (9.0) | |
| 30 | 79 | (78.2) | 88 | (72.1) | |
| <30 | 18 | (17.8) | 23 | (18.9) | .30 |
| KPS, No. (%) | |||||
| <70 | 34 | (34.0) | 49 | (42.2) | |
| ≥70 | 66 | (66.0) | 67 | (57.8) | .21 |
| RPA class, No. (%) | |||||
| I | 4 | (4.0) | 4 | (3.5) | |
| II | 62 | (62.0) | 63 | (54.3) | |
| III | 34 | (34.0) | 49 | (42.2) | .46 |
|
| |||||
CNS indicates central nervous system; ER, estrogen receptor; PR, progesterone receptor; WBRT, whole brain radiotherapy; Gy, grays; KPS, Karnofsky performance status; RPA, recursive partitioning analysis.